Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2102 in advanced gynecological malignancies
NCT06654440Phase 2Recruiting
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in gynecologic cancer, sponsored by Hengrui Therapeutics. Started Nov 2024; status: recruiting.
02
Drugs
SHR-A2102
03
Conditions
gynecologic cancer
Beyond the preview
Go deeper on NCT06654440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06654440.